Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral BI 3000202 in moderate to severe systemic lupus erythematosus
jRCT2071250153Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing BI 3000202 with Placebo (2 arms). Primary endpoint: SRI-4 response at Week 32. Started Apr 2026; status: recruiting.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071250153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250153.